Literature DB >> 23564912

The laboratory and the direct oral anticoagulants.

Armando Tripodi1.   

Abstract

Although direct oral anticoagulants do not need laboratory testing for dose adjustment, there are instances when laboratory measurement of the drug anticoagulant effect may be useful. They include before initiation of treatment, before surgical or invasive procedures, on the occasion of hemorrhagic or thrombotic events, and whenever immediate reversal of anticoagulation is needed. Choice of tests should be primarily based on their prompt availability. Accordingly, the dilute-thrombin or the ecarin clotting times are best suited for dabigatran and the prothrombin time or the anti-FXa for rivaroxaban.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23564912     DOI: 10.1182/blood-2012-12-453076

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Role of the anticoagulant monitoring service in 2018: beyond warfarin.

Authors:  Nathan P Clark
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Anticoagulation manager: development of a clinical decision support mobile application for management of anticoagulants.

Authors:  Pamela J Thompson; Julie R Taylor; Barbara A Zehnbauer; Karlyn K Wilson; May D Wang
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2016-08

Review 3.  The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.

Authors:  Armando Tripodi; Francesco Marongiu; Marco Moia; Gualtiero Palareti; Vittorio Pengo; Daniela Poli; Domenico Prisco; Sophie Testa; Maria Zanazzi
Journal:  Intern Emerg Med       Date:  2018-04-26       Impact factor: 3.397

4.  Italian intersociety consensus on DOAC use in internal medicine.

Authors:  Domenico Prisco; Walter Ageno; Cecilia Becattini; Armando D'Angelo; Giovanni Davì; Raimondo De Cristofaro; Francesco Dentali; Giovanni Di Minno; Anna Falanga; Gualberto Gussoni; Luca Masotti; Gualtiero Palareti; Pasquale Pignatelli; Roberto M Santi; Francesca Santilli; Mauro Silingardi; Antonella Tufano; Francesco Violi
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

5.  Direct oral anticoagulants in lipoprotein apheresis: handle with care.

Authors:  Francesco Sbrana; Beatrice Dal Pino; Angela Papa; Federico Bigazzi; Luca Panchetti; Tiziana Sampietro
Journal:  Intern Emerg Med       Date:  2019-06-04       Impact factor: 3.397

6.  Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants.

Authors:  E Grandone; D Barcellona; D Colaizzo; F Marongiu
Journal:  J Endocrinol Invest       Date:  2017-02-17       Impact factor: 4.256

7.  Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.

Authors:  Gianluca Gessoni; Sara Valverde; Letizia Valle; Pierpaolo Caruso; Francesca Gessoni; Roberto Valle
Journal:  Blood Transfus       Date:  2017-03-07       Impact factor: 3.443

8.  Laboratory tests during direct oral anticoagulant treatment.

Authors:  Armando Tripodi; Simon Braham; Marco Moia
Journal:  Intern Emerg Med       Date:  2014-02-04       Impact factor: 3.397

9.  Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Walter Ageno; Marcello Ciaccio; Cristina Legnani; Giuseppe Lippi; Cesare Manotti; Rossella Marcucci; Marco Moia; Benedetto Morelli; Daniela Poli; Agostino Steffan; Sophie Testa
Journal:  Blood Transfus       Date:  2017-09-13       Impact factor: 3.443

10.  The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on vitamin K antagonist.

Authors:  Doris Barcellona; Miro Luzza; Nicola Battino; Lara Fenu; Francesco Marongiu
Journal:  Intern Emerg Med       Date:  2014-12-09       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.